RxDoctor Payments Data

Brandi Mangan

Family · Fort Campbell, KYNPI 1578164760

Payments from drug & device makers

$1,804in general payments, 2019–2025

Across 74 payments — averaging $24.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Takeda Pharmaceuticals U.S.A., Inc.$504
  • AbbVie$486
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$321
  • Gilead$245
  • Johnson & Johnson$52
  • Celltrion USA Inc.$41
  • plus $153 from 8 others

What the payments were for

  • Food & beverage$1,75097%
  • Education$553%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,804 in reported general payments places this provider in the 75th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$29,004
Medicare patients
237
Services billed
313

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OcalivaObeticholic Acid13$125,405
CreonLipase/Protease/Amylase12$66,205
LinzessLinaclotide20$31,964
Dexlansoprazole DrDexlansoprazole31$9,072
Colestipol Hcl37$4,245
Pantoprazole Sodium241$4,049
Ursodiol15$2,982
Omeprazole170$2,637
Esomeprazole Magnesium25$2,383
Famotidine178$2,152
Budesonide DrBudesonide12$1,858
Lansoprazole23$1,131
Dicyclomine Hcl70$1,097
Sucralfate15$988
Ondansetron OdtOndansetron21$657

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Intercept Pharmaceuticals, Inc.Ocaliva$13$125,40513 claims
AbbVieCreon, Linzess$486$98,16932 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,374 family providers in Kentucky.

Other family in Fort Campbell

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →